0.69
+0.52%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cognition Therapeutics
From its filings with the US Securities and Exchange Commission
Cognition Therapeutics is based in Purchase, New York and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CGTX. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported a net loss of $23.5m. At that date it held total assets of $48.4m and shareholders' equity of $34.3m.
We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Currently available therapies for these diseases are limited, with many diseases having no approved therapies or treatments. Our goal is to develop disease-modifying treatments for patients with these degenerative disorders.
Our lead product candidate, zervimesine, also known as CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins including β-amyloid, or Aβ and ɑ-synuclein. These and similar protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer’s disease, or AD, and dementia with Lewy bodies, or DLB.
The United States Adopted Name (USAN) Council adopted zervimesine as the USAN for CT1812 in December 2024.
The Company’s initial focus was on the development of zervimesine for the treatment of AD. We believe our evidence demonstrates that zervimesine displaces Aβ oligomers from their neuronal receptors. Based on this mechanism, we believe zervimesine has the potential to slow the loss of synapses and cognitive decline observed in AD. The direct healthcare costs to care for patients with AD and other dementias in the United States is estimated to exceed $350 billion.
Quoted from its 10-K, filed 26 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 8 Oct 2021
- Employees
- 22
- Website
- cogrx.com ↗
- Head office
- 2500 WESTCHESTER AVE, PURCHASE, NY, 10577
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Jack KhattarIndependent Chairman of the Board$152,639
- Ms. Lisa RicciardiPresident, Chief Executive Officer, Director, since 2019$1.5m
- Mr. John DoyleChief Financial Officer$809,571
- Dr. Anthony CaggianoChief Medical Officer, Head of R&D$1.1m
- Dr. Aaron FletcherIndependent Director$78,389
- Dr. Brett MoniaIndependent Director$83,389
- Ms. Ellen RichstoneIndependent Director$87,389
- Ms. Peggy WallaceIndependent Director$79,889
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company is focused on developing small molecule therapeutics targeting CNS disorders.
- Lead product candidate CT1812 is designed to penetrate the blood-brain barrier.
- The company has a pipeline of product candidates targeting sigma-2 receptor complex.
Weaknesses
- The company has only 22 employees.
- The company went public in 2021 with limited commercialization experience.
- The company is engaged in the discovery and development of therapies for complex diseases.
Opportunities
- Potential to develop therapies for Alzheimer's disease and dry AMD.
- Opportunity to expand the pipeline targeting sigma-2 receptor complex.
- Growth potential in the pharmaceutical sector for CNS disorders.
Threats
- Competition in the pharmaceutical industry for CNS disorder treatments.
- High risk associated with drug development and commercialization.
- Dependence on successful clinical trials for product candidates.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.